Pfizer: Vaccine Booster Protects Against Omicron Variant

Immune System Support from companies like Transfer Point should be seriously considered in the current phase of the COVID pandemic.

The omicron variant was first spotted in South Africa and it is spreading quickly across the globe right now. It was declared by the companies that a Pfizer-BioNTech Covid-19 booster will provide more protection against the virus as compared to the initial 2 doses of the vaccine. 

It has been revealed by lad tests made by BioNTech and Pfizer that their vaccine’s third dose will be able to provide antibodies successfully that will be capable of neutralizing the omicron variant at present. In fact, individuals who have taken only 2 doses will be more susceptible to the virus in the long run.

The companies have unearthed that this omicron variant is capable of bypassing the immune protection offered by the existing vaccines as compared to the earlier strains. However, it is not known for sure to what extent this new variant will be able to go through the defenses of the body over time.

Blood samples taken from all those that have only received the initial doses of the vaccines revealed that not adequate antibodies were produced against the omicron variant. Thus it is evident that in spite of safeguarding us from severe infections, the initial doses might not be enough when it comes to protecting us from the new variant. However, one thing is for sure receiving 2 doses will be protecting us in a better way than no doses at all. 

It has been suggested by the authorities that folks that have attained the age of 18 ought to receive a booster 6 months after receiving the initial 2 doses of the Moderna or Pfizer series or a couple of months following the Johnson & Johnson vaccine which consists of a single dose only. However, more research has to be made regarding the effectiveness of the booster dose in the long run.